JPRN-UMIN000040561已完成未知
Efficacy and safety of omalizumab, an anti-IgE monoclonal antibody, in patients with seasonal allergic rhinitis: a systematic review. - omalizumab for seasonal allergic rhinitis
Showa University School of Medicine0 个研究点目标入组 2,270 人开始时间: 2020年6月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 2,270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Case reports, case-control studies, cohort studies, and single-arm studies.
研究者
相似试验
已完成
不适用
Efficacy and safety of omalizumab (anti-IgE monoclinal antibody) on oral immunotherapy for patients with cow's milk allergy (randomized control study)food allergyJPRN-UMIN000015545The Mami Mizutani foundation Kansai Medical University50
尚未招募
不适用
sefulness and safety of Omalizumab (anti-IgE monoclonal antibody) on oral immunotherapy for patients with severe food allergyFood allergyJPRN-UMIN000008688Kansai Medical University40
进行中（未招募）
1 期
A trial to see if anti-IgE (an antibody) will improve severe eczema that has not been cured by other types of medicineSevere eczema in childrenMedDRA version: 19.0 Level: LLT Classification code 10003641 Term: Atopic eczema System Organ Class: 100000004858MedDRA version: 19.0 Level: LLT Classification code 10014189 Term: Eczema allergic atopic System Organ Class: 100000004858EUCTR2010-020841-29-GBKing`s College London62
已完成
2 期
ANTI-IGE THERAPY (OMALIZUMAB) IN IGE-ACPA POSITIVE RHEUMATOID ARTHRITIS Addendum: An open label extension study to provide continuation of anti-IgE therapy to Rheumatoid Arthritis patients who participated in the TIGER study P10.161rheumatism1000381610023213rheumatoid arthritisNL-OMON37983eids Universitair Medisch Centrum80
进行中（未招募）
不适用
Clinical and biological effects of Anti-IgE (Omalizumab) in patients with bilateral nasal polyposis and asthmapatients with nasal polyps and comorbid asthmaMedDRA version: 8.1Level: LLTClassification code 10028756Term: Nasal polypsEUCTR2006-003524-11-BEniversity Hospital Gent